MDX2301 Clinical Trials (2026): 1 Studies for COVID-19 (Prevention) & COVID -19
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
1 MDX2301 clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 1 indication (including COVID-19 (Prevention) & COVID -19) and 80 total planned enrollment. 1 MDX2301 clinical trial is actively recruiting at 2 U.S. sites across 2 states. Most recent activity: NCT07445971 (Dec 2027).
Where to Participate: All MDX2301 Trial Sites in the U.S. (2 sites across 2 states)
Every actively recruiting MDX2301trial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| NV | TrialMed Clinical Research Unit | Las Vegas89113 | NCT07445971 | Map |
| TX | TrialMed Clinical Research Unit | Austin78744 | NCT07445971 | Map |
MDX2301 clinical trials at a glance: phase × recruitment status
| Phase | recruiting | Total |
|---|---|---|
| P1 | 1 | 1 |
Recruiting MDX2301 clinical trials (1)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT07445971 | A Study Evaluating MDX2301 in Healthy Adults and Adults at Higher Risk for Severe COVID-19. | P1 | COVID -19 | 80 | Mar 2026 |
All MDX2301 trials (1)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT07445971 | A Study Evaluating MDX2301 in Healthy Adults and Adults at Higher Risk for Severe COVID-19. | P1 | recruiting | 80 | ModeX Therapeutics, An OPKO Health Company | Mar 2026 |
MDX2301 clinical trials: frequently asked questions
- How many MDX2301 clinical trials are there?
- 1 MDX2301 clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 1 is actively recruiting participants.
- Are MDX2301 clinical trials recruiting in 2026?
- Yes — 1 MDX2301 trial is actively recruiting in 2026, with 2 U.S. sites across 2 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is MDX2301 being studied for?
- MDX2301 is being studied for COVID-19 (Prevention), COVID -19. The trials are grouped by indication on this page.
- What phase is MDX2301 in?
- MDX2301 clinical trials span 1 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors MDX2301 clinical trials?
- The lead sponsor across the most MDX2301 trials is ModeX Therapeutics, An OPKO Health Company. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming MDX2301as an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: